6 Misconceptions About Automating Cell Therapy Manufacturing

By Per Hammer, ‎Senior Global Product Manager, Cytiva and Alex Nancekievill, Chief Business Officer, Asymptote, Cytiva

Controlling quality and variability in drug manufacturing is essential to the safety and efficacy of pharmaceutical products. In biomanufacturing, increased adoption of automated systems is helping to facilitate these tasks while standardizing production. By using automation to minimize human interaction and time and resource requirements, you can increase your product’s speed to market and mitigate many of the risks and costs associated with commercialization.

These innovative solutions improve manufacturing efficiency and support rapidly growing industry sectors, such as cell therapy.  Cell therapies have burst onto the market with great promise to improve patient treatment options and alter clinical care. With the cell therapy market expected to reach over $8.8 billion by 2027¹, digitizing operations while keeping pace with this emerging space can prove challenging. To safely meet increasing demand, we need to reexamine how best to apply automated solutions.